Our experts have written, co-written, and provided insights into hundreds of publications.
Willis M, Asseburg C, He J. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). iHEA 2011. Podium. J Med Econ 2013;16(8):1007-21.
Willis M, Neslusan C, Asseburg C, et al. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association (ADA) meeting 2011. Podium.
Soini E, Martikainen J, et al. Cost-effectiveness of first-line rituximab maintenance treatment for follicular lymphoma. Haematologica 2011;96(s2):402. Poster at the Annual Congress of European Hematology Association (EHA 2011).
Asseburg C, et al. Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting. Clin Ther 2011;33(4):482-97.
Soini E, et al. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol 2011;22(1):215-23.
Soini E, Martikainen J, et al. Sequential treatment of follicular non-Hodgkin lymphoma: Cost-effectiveness and value of information. Value in Health 2011;14(7):A239-40. Podium at the Annual ISPOR European Congress.
Hallinen T, Soini E, et al. Differential use of extended and instant release quetiapine: A naturalistic study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. Value in Health 2011;14(7):A299.
Theidel U, Asseburg C, et al. Cost effectiveness of ticagrelor in the treatment of acute coronary syndrome in Germany. Annual ISPOR European Congress 2011. Value in Health 2011;14(7):A376-7.
Martikainen J, Soini E, et al. The health economic consequences of reducing salt and replacing intake of saturated fat with polyunsaturated fat in the adult Finnish population – Estimates based on the FINRISK and FINDIET studies. Eur J Clin Nutr 2011;65()10:1148-55.
Soini E. Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored. Ann Oncol 2011;22(6):1465-6.
Cummins E, Asseburg C, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health 2011;14(1):15-23.
Peura P, Asseburg C, Turunen J, Purmonen T, Martikainen J. Epäsuora vertailu ja verkostometa-analyysit – uudet työkalut lääkkeiden suhteellisen tehon ja vaikuttavuuden arviointiin. (Indirect comparison and network meta-analyses – new tools for the assessment of evidence on the relative efficacy of drugs.) Aikakauskirja Duodecim 2011;127(9):900-10.
Blomster H, et al. Impaired nasal breathing may prevent the beneficial effect of weight loss in the treatment of OSA. Rhinology 2011;49:587-92. Collaborators: Soini E, Martikainen J.
Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50(3):344-52.
Hallinen T, Soini E. The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis. The Open Pharmacoeconomics & Health Economics Journal 2011;3:6-10.
Soini E, Martikainen J, et al. Treatment of follicular non-Hodgkin lymphoma with or without rituximab: Cost-effectiveness and value of information based on 5-year follow-up. Ann Oncol 2011;22(5):1189-97.
Soini E. ESiOR laittaa numerot puhumaan. KunnallisSuomi 2010;(10):8.
Erntoft S, Asseburg C, et al. Vilken betydelse har hälsoekonomi vid prioriteringar? – Ett experiment bland beslutsfattare och en analys av faktiska prioriteringar. Linköping, Prioriteringscentrum 2010:3.
Martikainen J. Lääkehoitojen taloudellisen arvon arvioinnin perusperiaatteet. Onko lääke hintansa väärti? Lääkepäivät. Mar 19-20, 2010. Toim. Pirinen O, Aducate Reports and Books 1/2010: 78-79. Itä-Suomen yliopisto. Koulutus- ja kehittämispalvelu Aducate, Kuopio 2010. Podium.
Asseburg C. Experiences from The United Kingdom and Sweden in conducting pharmacoeconomic studies. Onko lääke hintansa väärti? Lääkepäivät. Mar 19-20, 2010. Toim. Pirinen O, Aducate Reports and Books 1/2010:80-81. Itä-Suomen yliopisto. Koulutus- ja kehittämispalvelu Aducate, Kuopio 2010. Podium.
Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry 2011;26(5):473-82.
Ryynänen OP, Laitinen T, Soini E, et al. Bayesian methods for predicting treatment results. ECHE 2010. Podium.
Soini E, Hallinen T. Health economic study using survey data and modelling: Agomelatine, generic venlafaxine and placebo in the treatment of major depressive disorder. European Conference on Health Economics (ECHE) 2010.
Asseburg C, Ramsberg J, Peura P, Henriksson M, Purmonen T, Turunen J, Martikainen J. A Bayesian assessment of decision uncertainty in the choice between triptans for the treatment of migraine in Finland. International Society for Bayesian Analysis (ISBA) 2010 World Meeting on Bayesian Statistics.
Peura P, Purmonen T, Turunen J, Martikainen J. Tulosmuuttujan määrittämiseen liittyvä malliepävarmuus kustannusvaikuttavuusanalyyseissä. Podium. In: Klavus J (ed.) Terveystaloustiede 2010. Helsinki: THL, 74–7.
Soini E. Cost-effectiveness of modern anticoagulation treatment. Session: Who benefits from modern anticoagulation treatment – Practical guidelines. Kardiologian päivät. Oct 14, 2010.
Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2010; syksy:4. Haastateltu: Soini, E.
Soini E. Trabektediinin kustannusvaikuttavuus edenneen pehmytkudossarkooman hoidossa. Harvinaiset sairaudet -päivä. Oct 29, 2010. Finlandia-talo, Helsinki. Podium.
Hallinen T, Soini E. The impact of Finnish pharmaceutical pricing scheme in cost-effectiveness analyses. Value in Health 2010;13(7):A249. Podium at the Annual ISPOR European Congress.
Soini E, Hallinen T, et al. Cost-effectiveness, value of information and budget impact of certolizumab pegol compared to subcutaneous tumor necrosis factor (TNF) inhibitors and methotrexate in the treatment of moderate-to-severe rheumatoid arthritis in Finland. Value Health 2010;13(7):A243. Podium at the Annual ISPOR European Congress.